Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas
Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predict...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2016-10-01
|
Series: | Balkan Medical Journal |
Subjects: | |
Online Access: | http://balkanmedicaljournal.org/text.php?lang=en&id=29 |
id |
doaj-a941accd41ad4cb09b80b59a161a3f2c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
İrfan Cicin Tahsin Özatlı Esma Türkmen Türkan Özturk Melike Özçelik Devrim Çabuk Ayşe Gökdurnalı Özlem Balvan Yaşar Yıldız Metin Şeker Nuriye Özdemir Burcu Yapar Özgür Tanrıverdi Yusuf Günaydin Serkan Menekşe Berna Öksüzoğlu Asude Aksoy Bülent Erdoğan M. Bekir Hacıoglu Erkan Arpaci Alper Sevinç Mehmet Atilla Uysal Sinem İliaz |
spellingShingle |
İrfan Cicin Tahsin Özatlı Esma Türkmen Türkan Özturk Melike Özçelik Devrim Çabuk Ayşe Gökdurnalı Özlem Balvan Yaşar Yıldız Metin Şeker Nuriye Özdemir Burcu Yapar Özgür Tanrıverdi Yusuf Günaydin Serkan Menekşe Berna Öksüzoğlu Asude Aksoy Bülent Erdoğan M. Bekir Hacıoglu Erkan Arpaci Alper Sevinç Mehmet Atilla Uysal Sinem İliaz Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas Balkan Medical Journal Carcinosarcoma ovary uterine predictive factors prognostic factors |
author_facet |
İrfan Cicin Tahsin Özatlı Esma Türkmen Türkan Özturk Melike Özçelik Devrim Çabuk Ayşe Gökdurnalı Özlem Balvan Yaşar Yıldız Metin Şeker Nuriye Özdemir Burcu Yapar Özgür Tanrıverdi Yusuf Günaydin Serkan Menekşe Berna Öksüzoğlu Asude Aksoy Bülent Erdoğan M. Bekir Hacıoglu Erkan Arpaci Alper Sevinç Mehmet Atilla Uysal Sinem İliaz |
author_sort |
İrfan Cicin |
title |
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas |
title_short |
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas |
title_full |
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas |
title_fullStr |
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas |
title_full_unstemmed |
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas |
title_sort |
predictive and prognostic factors in ovarian and uterine carcinosarcomas |
publisher |
Galenos Publishing House |
series |
Balkan Medical Journal |
issn |
2146-3123 2146-3131 |
publishDate |
2016-10-01 |
description |
Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT.
Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS).
Study Design: Retrospective cross-sectional study
Methods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were included in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.
Results: Age (≥70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6).Adjuvant chemotherapy had no effect on OS (p=0.15).Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors.
Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS. |
topic |
Carcinosarcoma ovary uterine predictive factors prognostic factors |
url |
http://balkanmedicaljournal.org/text.php?lang=en&id=29 |
work_keys_str_mv |
AT irfancicin predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT tahsinozatlı predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT esmaturkmen predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT turkanozturk predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT melikeozcelik predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT devrimcabuk predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT aysegokdurnalı predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT ozlembalvan predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT yasaryıldız predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT metinseker predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT nuriyeozdemir predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT burcuyapar predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT ozgurtanrıverdi predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT yusufgunaydin predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT serkanmenekse predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT bernaoksuzoglu predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT asudeaksoy predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT bulenterdogan predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT mbekirhacıoglu predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT erkanarpaci predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT alpersevinc predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT mehmetatillauysal predictiveandprognosticfactorsinovariananduterinecarcinosarcomas AT sinemiliaz predictiveandprognosticfactorsinovariananduterinecarcinosarcomas |
_version_ |
1725508327245348864 |
spelling |
doaj-a941accd41ad4cb09b80b59a161a3f2c2020-11-24T23:41:00ZengGalenos Publishing HouseBalkan Medical Journal2146-31232146-31312016-10-01335517524 10.5152/balkanmedj.2016.151268Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomasİrfan Cicin0Tahsin Özatlı1Esma Türkmen2Türkan Özturk3Melike Özçelik4Devrim Çabuk5Ayşe Gökdurnalı6Özlem Balvan7Yaşar Yıldız8Metin Şeker9Nuriye Özdemir10Burcu Yapar11Özgür Tanrıverdi12Yusuf Günaydin13Serkan Menekşe14Berna Öksüzoğlu15Asude Aksoy16Bülent Erdoğan17M. Bekir Hacıoglu18Erkan Arpaci19Alper Sevinç20Mehmet Atilla Uysal21Sinem İliaz22Department of Medical Oncology, Trakya University School of Medicine, Edirne, TurkeyDepartment of Medical Oncology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TurkeyDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, TurkeyDepartment of Medical Oncology, Karadeniz Technical University School of Medicine, Trabzon, TurkeyDepartment of Medical Oncology, Dr. Lütfi Kırdar Research and Training Hospital, İstanbul, TurkeyDepartment of Medical Oncology, Kocaeli University School of Medicine, Kocaeli, TurkeyDepartment of Medical Oncology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TurkeyDepartment of Medical Oncology, Dr. Lütfi Kırdar Research and Training Hospital, İstanbul, TurkeyDepartment of Medical Oncology, Atatürk Research and Training Hospital, İzmir, TurkeyDepartment of Medical Oncology, Cumhuriyet University School of Medicine, Sivas, TurkeyDepartment of Medical Oncology, Ankara Numune Research and Training Hospital, Ankara, TurkeyDepartment of Medical Oncology, Pamukkale University School of Medicine, Denizli, TurkeyDepartment of Medical Oncology, Muğla University School of Medicine, Muğla, TurkeyDepartment of Medical Oncology, Gazi University School of Medicine, Ankara, TurkeyDepartment of Medical Oncology, Celal Bayar University School of Medicine, Manisa, TurkeyDepartment of Medical Oncology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TurkeyDepartment of Medical Oncology, İnönü University School of Medicine, Malatya, TurkeyDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, TurkeyDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, TurkeyDepartment of Medical Oncology, Sakarya Research and Training Hospital, Sakarya, TurkeyDepartment of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, TurkeyDepartment of Pulmonology, Yedikule Training and Research Hospital for Chest Diseases and Thoracic Surgery, İstanbul, TurkeyDepartment of Pulmonology, Yedikule Training and Research Hospital for Chest Diseases and Thoracic Surgery, İstanbul, TurkeyBackground: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT. Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS). Study Design: Retrospective cross-sectional study Methods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were included in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study. Results: Age (≥70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6).Adjuvant chemotherapy had no effect on OS (p=0.15).Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors. Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS.http://balkanmedicaljournal.org/text.php?lang=en&id=29Carcinosarcomaovaryuterinepredictive factorsprognostic factors |